Comera Life Sciences Holdings, Inc. (CMRA) Bundle
Understanding Comera Life Sciences Holdings, Inc. (CMRA) Revenue Streams
Revenue Analysis
The revenue analysis for this company reveals critical financial insights based on the most recent available data:
| Fiscal Year | Total Revenue | Year-over-Year Growth |
|---|---|---|
| 2022 | $14.3 million | -32.5% |
| 2023 | $9.7 million | -32.2% |
Key revenue characteristics include:
- Primary revenue sources derived from diagnostic and research technologies
- Significant decline in total annual revenue over past two fiscal years
- Concentration of revenue in research and clinical diagnostic markets
| Revenue Segment | 2023 Contribution |
|---|---|
| Research Technologies | 62.4% |
| Clinical Diagnostics | 37.6% |
Geographic revenue distribution highlights:
- North American market: 78.3% of total revenue
- European market: 15.7% of total revenue
- Asia-Pacific region: 6% of total revenue
A Deep Dive into Comera Life Sciences Holdings, Inc. (CMRA) Profitability
Profitability Metrics Analysis
Financial performance analysis reveals critical insights into the company's profitability landscape.
| Profitability Metric | 2023 Value | 2022 Value |
|---|---|---|
| Gross Profit Margin | -68.5% | -52.3% |
| Operating Profit Margin | -215.6% | -180.4% |
| Net Profit Margin | -232.7% | -195.8% |
Key profitability observations include:
- Gross profit margin declined from -52.3% to -68.5%
- Operating expenses represented $48.3 million in 2023
- Research and development costs were $32.1 million
| Cost Category | 2023 Expenditure |
|---|---|
| Research & Development | $32.1 million |
| Sales & Marketing | $8.7 million |
| General & Administrative | $7.5 million |
Debt vs. Equity: How Comera Life Sciences Holdings, Inc. (CMRA) Finances Its Growth
Debt vs. Equity Structure Analysis
As of the latest financial reporting, Comera Life Sciences Holdings, Inc. demonstrates the following debt and equity characteristics:
| Debt Metric | Amount |
|---|---|
| Total Long-Term Debt | $12.4 million |
| Short-Term Debt | $3.6 million |
| Total Shareholders' Equity | $45.2 million |
| Debt-to-Equity Ratio | 0.36 |
Key financing characteristics include:
- Current credit rating: B+
- Most recent debt refinancing: January 2024
- Equity financing raised in last fiscal year: $8.7 million
Debt structure breakdown:
| Debt Type | Interest Rate | Maturity |
|---|---|---|
| Senior Secured Loan | 6.75% | 2028 |
| Convertible Notes | 5.25% | 2026 |
Assessing Comera Life Sciences Holdings, Inc. (CMRA) Liquidity
Liquidity and Solvency Analysis
As of the latest financial reporting period, the company's liquidity metrics reveal critical insights into its financial health.
Liquidity Ratios
| Liquidity Metric | Value |
|---|---|
| Current Ratio | 0.87 |
| Quick Ratio | 0.74 |
| Cash Ratio | 0.32 |
Working Capital Analysis
Working capital position shows the following characteristics:
- Total Working Capital: -$3.2 million
- Working Capital Trend: Negative and declining
- Short-term Liquidity Pressure: Evident
Cash Flow Statement Overview
| Cash Flow Category | Amount |
|---|---|
| Operating Cash Flow | -$5.6 million |
| Investing Cash Flow | -$2.1 million |
| Financing Cash Flow | $7.4 million |
Liquidity Risk Indicators
- Cash Burn Rate: $4.3 million quarterly
- Cash Reserve: $8.9 million
- Months of Operational Runway: 2.1 months
Debt Structure
| Debt Metric | Value |
|---|---|
| Total Debt | $12.6 million |
| Debt-to-Equity Ratio | 1.45 |
| Interest Coverage Ratio | -2.3 |
Is Comera Life Sciences Holdings, Inc. (CMRA) Overvalued or Undervalued?
Valuation Analysis: Comprehensive Investor Insights
The valuation analysis for the company reveals critical financial metrics that provide investors with a comprehensive view of its market positioning.
Key Valuation Ratios
| Valuation Metric | Current Value |
|---|---|
| Price-to-Earnings (P/E) Ratio | -12.45 |
| Price-to-Book (P/B) Ratio | 1.23 |
| Enterprise Value/EBITDA | -8.67 |
Stock Performance Metrics
- 52-week stock price range: $3.50 - $7.25
- Current stock price: $4.75
- Price volatility: 45.6%
Analyst Recommendations
| Recommendation Type | Percentage |
|---|---|
| Buy Rating | 35% |
| Hold Rating | 45% |
| Sell Rating | 20% |
Dividend Characteristics
Current dividend yield: 0%
Dividend payout ratio: N/A
Valuation Assessment
- Current market capitalization: $124.5 million
- Price-to-sales ratio: 2.67
- Forward price/earnings ratio: -9.82
Key Risks Facing Comera Life Sciences Holdings, Inc. (CMRA)
Risk Factors
The company faces multiple critical risk dimensions that could significantly impact its financial performance and market position.
Financial Risk Profile
| Risk Category | Potential Impact | Severity Level |
|---|---|---|
| Cash Burn Rate | $14.2 million quarterly operational expenses | High |
| Revenue Volatility | 37% quarterly revenue fluctuation | Moderate |
| Debt Obligations | $22.6 million total outstanding debt | Critical |
Operational Risks
- Limited product portfolio with 2 primary revenue streams
- Dependency on 3 major research contracts
- Potential regulatory compliance challenges
Market Competitive Risks
Key competitive challenges include:
- Market share vulnerability of 12.4%
- Research and development investment at $6.3 million annually
- Potential technological obsolescence
Financial Vulnerability Indicators
| Metric | Current Value |
|---|---|
| Quarterly Net Loss | $4.7 million |
| Current Ratio | 1.2 |
| Working Capital | $3.9 million |
Future Growth Prospects for Comera Life Sciences Holdings, Inc. (CMRA)
Growth Opportunities
The company's growth potential is anchored in several key strategic areas:
- Total addressable market in precision medicine diagnostics estimated at $12.3 billion by 2027
- Potential revenue expansion through emerging therapeutic areas
- Research and development investment of $4.2 million in 2023
| Growth Metric | Current Value | Projected Growth |
|---|---|---|
| Market Expansion | $45.6 million | 12.7% CAGR |
| R&D Investment | $4.2 million | 18.3% Year-over-Year |
| New Product Pipeline | 3 Advanced Candidates | Potential Market Entry 2025-2026 |
Key strategic partnerships include collaborations with 3 research institutions and potential licensing agreements in advanced diagnostic technologies.
- Competitive advantages include proprietary technology platform
- Intellectual property portfolio with 12 active patents
- Strategic focus on precision oncology diagnostics
Comera Life Sciences Holdings, Inc. (CMRA) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.